MODD

Submission Covers Software Enhancements for Patient Flexibility and Customization of Pivot SAN DIEGO, CA / ACCESS Newswire / July 1, 2026 / Modular Medical, Inc. ("Modular Medical" or "the Company") (NASDAQ:MODD), a leader in innovative, patient-centric insulin delivery technology, today announced submission to the U.S. Food & Drug Administration (FDA) of a series of software enhancements to its PivotTM insulin delivery system, providing users with more customization options and user-interface (UI) improvements, as well as other software upgrades. "This submission is the first of a series of further improvements and upgrades planned for the Pivot platform, now that our core form factor has been cleared by the FDA and is in the market.

First Patients Began Device Training and Insulin Delivery Today, Marking Transition to a Commercial Company Pivot is the First Insulin Pump Designed to Address the Large, Underserved Population of Insulin-Dependent Adults Still Relying on Multiple Daily Injections, a Multibillion-Dollar Market SAN DIEGO, CO / ACCESS Newswire / June 30, 2026 / Modular Medical, Inc. ("Modular Medical" or "the Company") (NASDAQ:MODD), a leader in innovative, patient-centric insulin delivery technology, today announced that the first patients have completed onboarding and training and are now actively using the Pivot™ tubeless insulin patch pump in real-world settings. This milestone marks the transition of the Pivot pump from development into active patient use and represents a significant step in Modular Medical's commercialization strategy.

Pivot starter kits are now shipping to multiple endocrinology practices SAN DIEGO, CA / ACCESS Newswire / June 26, 2026 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), a leader in innovative, patient-centric insulin delivery technology, today announced that the Pivot™ tubeless insulin patch pump is now shipping to physician offices for training. Upon completion of training, these pumps will be presented to potential patients in the next few days and weeks.

The Pivot tubeless insulin patch pump is now commercially available in the U.S. following FDA 510(k) clearance in April Pivot represents a differentiated solution for insulin-dependent adults still on multiple daily injections, representing a multi-billion-dollar market Commercial expansion activities are expected to begin in Q4 2026 SAN DIEGO, CA / ACCESS Newswire / June 24, 2026 / Modular Medical, Inc. (NASDAQ:MODD), a leader in innovative, patient-centric insulin delivery technology, today announced that the Pivot™ tubeless insulin patch pump is now commercially available. This marks the start of real-world patient use, and the Company's transition to a commercial-stage medical device company.

Initial patients expected in June 2026 SAN DIEGO, CA / ACCESS Newswire / June 4, 2026 / Modular Medical, Inc. ("Modular Medical" or the "Company") (NASDAQ:MODD), a leader in innovative, patient-centric insulin delivery, today announced the launch of PivotPump.com, a patient-focused website designed to support individuals seeking a simpler path to insulin pump therapy. This launch follows the Company's receipt of U.S. Food and Drug Administration ("FDA") clearance in April 2026 for its Pivot™ insulin delivery system.

Meet with Modular Medical CEO Jeb Besser There are 4.8 million individuals with diabetes in the US that require daily insulin. Only 20% currently use an insulin pump.

SAN DIEGO, CA / ACCESS Newswire / April 19, 2026 / Modular Medical, Inc. ("Modular Medical" or the "Company") (NASDAQ:MODD), a leader in innovative, patient-centric insulin delivery, today announced the pricing of a registered direct offering (the "Offering") consisting of 750,000 shares of the Company's common stock at an offering price of $4.50 per share. The gross proceeds to the Company from the Offering are estimated to be approximately $3.4 million before deducting placement agent fees and other offering expenses.

SAN DIEGO, CA / ACCESS Newswire / April 16, 2026 / Modular Medical, Inc. ("Modular Medical" or the "Company") (NASDAQ:MODD), a leader in innovative, patient-centric insulin delivery, today announced that it has received a letter from the Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it has regained compliance with the Nasdaq Capital Market's minimum bid price continued listing requirement. The letter noted that, as of April 14, 2026, the Company evidenced a closing bid price of its common stock in excess of the $1.00 minimum requirement for the last 10 consecutive trading days.